Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract
Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the contract from the U.
Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Moderna Inc.’s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback